Navigation Links
St. Jude announces breakthrough in eye cancer treatment

Scientists at St. Jude Children's Research Hospital have demonstrated in a mouse model a new, locally applied treatment for the eye cancer retinoblastoma that not only greatly reduces the size of the tumor, but does so without causing the side effects common with standard chemotherapy. The treatment also appears to be suitable for certain forms of breast, lung, prostate and colon cancer, and is simple enough for widespread use even in countries with limited resources.

A report on this work appears in the Nov. 2 issue of the journal Nature.

Retinoblastoma occurs in about 5,000 young children worldwide each year, arising from the immature retina, which is the part of the eye responsible for detecting light and color. The cancer is fatal if left untreated.

The new treatment holds promise for a simpler, more effective and less-toxic treatment for retinoblastoma that would eliminate the need for the current, complex therapy, according to senior author Michael Dyer, Ph.D., a Pew Scholar and associate member of the St. Jude Department of Developmental Neurobiology. The treatment is based on a discovery by Dyer's laboratory that overturned a widely held belief about the process of apoptosis (cell suicide) in retinoblastoma. Apoptosis is the way the body rids itself of abnormal cells that might become cancerous or cause other problems.

Until now, retinoblastoma experts thought that a mechanism called the p53 pathway triggered apoptosis in other types of cancer cells, but not in retinoblastoma. However, the St. Jude team proved not only that the p53 pathway was activated in early-stage retinoblastoma, but that excessive levels of a molecule called MDMX blocked it from triggering apoptosis in more advanced tumors. Based on this discovery, the St. Jude team used a molecule called nutlin-3 to block MDMX in retinoblastoma cells in test tube studies as well as in mouse models. The molecule was originally developed by

Roche Pharmaceuti
'"/>

Source:St. Jude Children's Research Hospital


Page: 1 2 3 4

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
4. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
5. GlycoFi announces the first production of antibodies with human glycosylation in yeast
6. NHGRI announces new sequencing targets
7. CHAVI announces international search for genes affecting HIV response
8. NHGRI announces latest sequencing targets
9. MUHC announces a transplant first in Quebec
10. NIH announces phase III clinical trial of creatine for Parkinsons disease
11. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Jude announces breakthrough eye cancer treatment

(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
(Date:6/23/2015)... 23, 2015   MedNet Solutions , an ... entire spectrum of clinical research, is pleased to ... , the company,s intuitive, flexible and affordable cloud-based ... 2015 Stevie® Award by the American Business ... Website category.  The American Business Awards are considered ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... study in the September 6 issue of the Journal of ... an important ciliary protein, CEP290. The results could be applied ... Mutations in human CEP290 cause cilia-related disorders that range in ... known to cause Meckel syndrome, Joubert syndrome, and NPHPthe most ...
... bacterial cells that act in their own interests ... can actually reduce the severity of infection. ... could be exploited to treat antibiotic-resistant infections, according ... General Microbiology,s autumn meeting today. Bacteria work ...
... Society is delighted to announce its 2011 Society Fellows. ... in science, contributions to the expansion of the field ... Fellows will be honored at the Awards Ceremony during ... 7, 2011 at the Baltimore Convention Center in Baltimore, ...
Cached Biology News:Backstabbing bacteria: A new treatment for infection? 2
(Date:7/2/2015)... ... 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), a ... the acquisition of Turner Medical, Inc ., thus becoming a global leader ... Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s product offering, ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market is ... the molecular diagnostics industry. BCC Research reveals in its new report that the market ... costs, and a growing need for better diagnostics as part of a molecular diagnostics ...
(Date:7/1/2015)... , July 1, 2015 Isagenix International, ... has earned three Gold, three Silver, and three Bronze ... gala held in Chicago this ... the premier business awards program in the U.S. ... our company,s strength in developing leaders, cultivating talent, creating ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical ... new Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. ... that will increase healthcare worker safety and reduce financial costs. , CTI Electronics ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... (EST):, "CYT006-AngQb, a Vaccine Against Hypertension Targeting Angiotensin II, ... Pressure.", The American Heart Association Publishes Today an Independent News Release ... ... no, Vaccine-Related Adverse Events Reported in 12 Months Follow-Up Period., ...
... Solutions Diagnostics, ERLANGEN, Germany, Nov. 6 ... Dade Behring Holdings, Inc. The,laboratory diagnostics company ... Diagnostics. As the market leader in the ... diagnostics, Siemens now can offer its,customers a ...
... November 6 AIM-quoted drug discovery,company Verona Pharma ... the planned development of its anti-asthma and hay ... compound, RPL554, is now entering a,second 28-day experimental ... demonstrate safety, before moving onto the proof of ...
Cached Biology Technology:Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 2Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 3Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 4Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 5Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 6Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 7Siemens Completes Acquisition of Dade Behring 2Siemens Completes Acquisition of Dade Behring 3AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies 2
... polystyrene with frosted labeling surfaces, volume ... counting. 100% integrity tested. Linkage: This ... number, created to easily match Cornings ... yet, please order under the old ...
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
... The high-throughput fluidics (HTF) system, 100-240 V, ... suspension array system that automates delivery of ... into the Bio-Plex array reader. The HTF ... nonpressurized bulk sheath container to constantly maintain ...
... Disposable. Virgin, optically clear polystyrene with ... alphanumeric coordinates for cell counting. 100% ... is a new product number, created ... If showing no availability yet, please ...
Biology Products: